Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia
Viatris said the U.S. Food and Drug Administration approved RYZUMVI for the treatment of presbyopia, according to the company's announcement.
Viatris
Services: Global healthcare company formed in November 2020 via Mylan-Upjohn combination; portfolio spans branded (Xulane, Yupelri, Effient, Dilantin, Cordarone, Sarafem, Dymista), generics (~1,400 molecules across all therapeutic areas), biosimilars, complex generics; therapeutic focus: cardiology, infectious disease, immunology, oncology, ophthalmology, dermatology, respiratory, CNS; significant emerging markets presence through legacy Mylan platforms; now executing Phase II of strategic plan with portfolio optimization
Company Info
Sector:Generic & Specialty Pharmaceuticals
Headquarters:Pittsburgh, PA, USA
Founded:1961
Website:www.viatris.com/
Upcoming Milestones & Key Dates
Q3/Q4 2026
Earnings
Q2 2026 earnings call
Recent News
Viatris builds in pain relief with $1.65bn Pacira purchase
Viatris is acquiring Pacira BioSciences in a $1.65 billion deal that adds non-opioid pain-management products to its portfolio.